Fennec Pharmaceuticals Files 8-K on Financials
Ticker: FENC · Form: 8-K · Filed: Mar 25, 2024 · CIK: 1211583
| Field | Detail |
|---|---|
| Company | Fennec Pharmaceuticals Inc. (FENC) |
| Form Type | 8-K |
| Filed Date | Mar 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
FENNEC PHARMACEUTICALS INC. FILED AN 8-K ON 3/25/24 DETAILING FINANCIALS.
AI Summary
Fennec Pharmaceuticals Inc. filed an 8-K on March 25, 2024, reporting results of operations and financial condition as of March 21, 2024. The filing details financial statements and exhibits related to the company's performance.
Why It Matters
This filing provides investors with an update on Fennec Pharmaceuticals' financial health and operational results, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing with no immediate significant events or changes indicated.
Key Players & Entities
- Fennec Pharmaceuticals Inc. (company) — Registrant
- March 21, 2024 (date) — Date of earliest event reported
- March 25, 2024 (date) — Date of report
- 001-32295 (company) — Commission File Number
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Fennec Pharmaceuticals Inc.'s Results of Operations and Financial Condition, including Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on March 21, 2024.
What is the Commission File Number for Fennec Pharmaceuticals Inc.?
The Commission File Number for Fennec Pharmaceuticals Inc. is 001-32295.
What is the SIC code for Fennec Pharmaceuticals Inc.?
The Standard Industrial Classification (SIC) code for Fennec Pharmaceuticals Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Where is Fennec Pharmaceuticals Inc. incorporated?
Fennec Pharmaceuticals Inc. is incorporated in British Columbia, Canada.
Filing Stats: 480 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-03-25 16:05:56
Filing Documents
- tm249737d1_8k.htm (8-K) — 25KB
- tm249737d1_ex99-1.htm (EX-99.1) — 120KB
- tm249737d1_ex99-1img001.jpg (GRAPHIC) — 2KB
- 0001104659-24-038444.txt ( ) — 332KB
- fencf-20240321.xsd (EX-101.SCH) — 3KB
- fencf-20240321_lab.xml (EX-101.LAB) — 33KB
- fencf-20240321_pre.xml (EX-101.PRE) — 22KB
- tm249737d1_8k_htm.xml (XML) — 4KB
02
Item 2.02. Results of Operations and Financial Condition. On March 21, 2024, Fennec Pharmaceuticals Inc. issued a news release announcing full year and fourth quarter financial results for the period ended December 31, 2023. A copy of the news release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act"), or incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, unless such subsequent filing specifically references this Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description Exhibit 99.1 Press Release dated March 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. FENNEC PHARMACEUTICALS INC. Date March 25, 2024 By: /s/ Robert Andrade Robert Andrade Chief Financial Officer